378 related articles for article (PubMed ID: 27289487)
1. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
Whiteley WN; Emberson J; Lees KR; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg MG; Lindley RI; Lyden P; Olivot JM; Parsons M; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Del Zoppo GJ; Sandercock P; Hacke W; Baigent C;
Lancet Neurol; 2016 Aug; 15(9):925-933. PubMed ID: 27289487
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
[TBL] [Abstract][Full Text] [Related]
3. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
[TBL] [Abstract][Full Text] [Related]
4. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
[TBL] [Abstract][Full Text] [Related]
5. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
[TBL] [Abstract][Full Text] [Related]
6. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
[TBL] [Abstract][Full Text] [Related]
7. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
Wahlgren N; Ahmed N; Dávalos A; Hacke W; Millán M; Muir K; Roine RO; Toni D; Lees KR;
Lancet; 2008 Oct; 372(9646):1303-9. PubMed ID: 18790527
[TBL] [Abstract][Full Text] [Related]
8. Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
Dorado L; Millán M; Pérez de la Ossa N; Guerrero C; Gomis M; Aleu A; López-Cancio E; Cuadras P; Dávalos A
Eur J Neurol; 2012 Sep; 19(9):1251-5. PubMed ID: 22568604
[TBL] [Abstract][Full Text] [Related]
9. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
Wahlgren N; Ahmed N; Eriksson N; Aichner F; Bluhmki E; Dávalos A; Erilä T; Ford GA; Grond M; Hacke W; Hennerici MG; Kaste M; Köhrmann M; Larrue V; Lees KR; Machnig T; Roine RO; Toni D; Vanhooren G;
Stroke; 2008 Dec; 39(12):3316-22. PubMed ID: 18927461
[TBL] [Abstract][Full Text] [Related]
10. Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
Külkens S; Hacke W
Expert Rev Neurother; 2007 Jul; 7(7):783-8. PubMed ID: 17610385
[TBL] [Abstract][Full Text] [Related]
11. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
[TBL] [Abstract][Full Text] [Related]
12. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Mazya M; Egido JA; Ford GA; Lees KR; Mikulik R; Toni D; Wahlgren N; Ahmed N;
Stroke; 2012 Jun; 43(6):1524-31. PubMed ID: 22442178
[TBL] [Abstract][Full Text] [Related]
13. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
[TBL] [Abstract][Full Text] [Related]
14. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
Goyal M; Menon BK; van Zwam WH; Dippel DW; Mitchell PJ; Demchuk AM; Dávalos A; Majoie CB; van der Lugt A; de Miquel MA; Donnan GA; Roos YB; Bonafe A; Jahan R; Diener HC; van den Berg LA; Levy EI; Berkhemer OA; Pereira VM; Rempel J; Millán M; Davis SM; Roy D; Thornton J; Román LS; Ribó M; Beumer D; Stouch B; Brown S; Campbell BC; van Oostenbrugge RJ; Saver JL; Hill MD; Jovin TG;
Lancet; 2016 Apr; 387(10029):1723-31. PubMed ID: 26898852
[TBL] [Abstract][Full Text] [Related]
15. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
; Sandercock P; Wardlaw JM; Lindley RI; Dennis M; Cohen G; Murray G; Innes K; Venables G; Czlonkowska A; Kobayashi A; Ricci S; Murray V; Berge E; Slot KB; Hankey GJ; Correia M; Peeters A; Matz K; Lyrer P; Gubitz G; Phillips SJ; Arauz A
Lancet; 2012 Jun; 379(9834):2352-63. PubMed ID: 22632908
[TBL] [Abstract][Full Text] [Related]
16. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
Wardlaw JM; Murray V; Berge E; del Zoppo G; Sandercock P; Lindley RL; Cohen G
Lancet; 2012 Jun; 379(9834):2364-72. PubMed ID: 22632907
[TBL] [Abstract][Full Text] [Related]
17. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
Wahlgren N; Ahmed N; Dávalos A; Ford GA; Grond M; Hacke W; Hennerici MG; Kaste M; Kuelkens S; Larrue V; Lees KR; Roine RO; Soinne L; Toni D; Vanhooren G;
Lancet; 2007 Jan; 369(9558):275-82. PubMed ID: 17258667
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
[TBL] [Abstract][Full Text] [Related]
19. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2013 Aug; 12(8):768-76. PubMed ID: 23791822
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
Bivard A; Zhao H; Churilov L; Campbell BCV; Coote S; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski AH; Dos Santos A; Ng JL; Yogendrakumar V; Ng F; Langenberg F; Easton D; Warwick A; Mackey E; MacDonald A; Sharma G; Stephenson M; Smith K; Anderson D; Choi P; Thijs V; Ma H; Cloud GC; Wijeratne T; Olenko L; Italiano D; Davis SM; Donnan GA; Parsons MW;
Lancet Neurol; 2022 Jun; 21(6):520-527. PubMed ID: 35525251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
